Integra Lifesciences (NASDAQ: IART) and Precipio (NASDAQ:PRPO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.
Valuation and Earnings
This table compares Integra Lifesciences and Precipio’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Integra Lifesciences||$1.19 billion||4.91||$64.74 million||$1.94||34.24|
|Precipio||$1.72 million||5.52||-$20.69 million||N/A||N/A|
Integra Lifesciences has higher revenue and earnings than Precipio.
This is a breakdown of recent recommendations for Integra Lifesciences and Precipio, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Integra Lifesciences presently has a consensus target price of $60.00, suggesting a potential downside of 9.68%. Given Integra Lifesciences’ higher possible upside, equities analysts plainly believe Integra Lifesciences is more favorable than Precipio.
This table compares Integra Lifesciences and Precipio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
79.5% of Integra Lifesciences shares are held by institutional investors. Comparatively, 11.4% of Precipio shares are held by institutional investors. 5.1% of Integra Lifesciences shares are held by insiders. Comparatively, 13.1% of Precipio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Integra Lifesciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Precipio has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Integra Lifesciences beats Precipio on 9 of the 11 factors compared between the two stocks.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Precipio Company Profile
Precipio, Inc. provides platform to eradicate the problem of misdiagnosis within academic institutions. The company also delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.